Revolutionizing Oral Drug Development in Atopic Dermatitis

Time: 11:30 am
day: Day 2 AM - Track A


  • Championing the specificity of the CCR4 target in atopic dermatitis
  • Delivering an orally administered small molecule with efficacious potency
  • Validating phase 1 studies with transcriptomic biomarker analyses to enable phase 2 progression